AXERT® (almotriptan malate) Tablets
(almotriptan malate) Tablets
AXERT® (almotriptan malate) Tablets
CONCERTA® (methylphenidate HCI) Extended-release Tablets CII
DARZALEX® (daratumumab)
DOXIL® (doxorubicin HCl liposome injection)
DURAGESIC® (fentanyl transdermal system) CII
EDURANT® (rilpivirine)
ELMIRON® (pentosan polysulfate sodium) Capsules
HALDOL® (haloperidol)
HALDOL® DECANOATE (haloperidol)
HALDOL® DECANOATE
INTELENCE® (etravirine)
INVEGA® (paliperidone)
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA SUSTENNA®
INVEGA TRINZA® (paliperidone palmitate) extended-release injectable suspension 273 mg, 410 mg, 546 mg, or 819 mg
INVEGA TRINZA®
INVOKAMET® (canagliflozin/metformin HCl) tablets
INVOKAMET® XR (canagliflozin/metformin HCl extended-release) tablets
INVOKAMET® XR
INVOKANA® (canagliflozin)
LEVAQUIN® (levofloxacin) Tablets
OLYSIO® (simeprevir)
OneTouch® Meters and Test Strips
ORTHO TRI-CYCLEN® Lo (norgestimate/ethinyl estradiol)
ORTHO TRI-CYCLEN® Lo
PANCREAZE® (pancrelipase) Delayed-Release Capsules
PREZCOBIX® (darunavir 800 mg/ cobicistat 150 mg) tablets
PREZISTA® (darunavir) tablets
PROCRIT® (epoetin alfa)
RAZADYNE® ER (galantamine HBr) Extended-Release Capsules
RAZADYNE® ER
REMICADE® (infliximab)
RISPERDAL® (risperidone)
RISPERDAL CONSTA® (risperidone)
RISPERDAL CONSTA®
SIMPONI® (golimumab)
SIMPONI ARIA® (golimumab)
SIMPONI ARIA®
SPORANOX® (itraconazole)
STELARA® (ustekinumab)
SYLVANT® (siltuximab)
TOPAMAX® (topiramate) Tablets
XARELTO® (rivaroxaban)
YONDELIS® (trabectedin)
ZYTIGA® (abiraterone acetate)

Need help paying for your AXERT® (almotriptan malate) Tablets prescription?

We want to guide you to programs that may help. Here you'll find the financial assistance programs available for AXERT®. We have also listed most of the eligibility requirements for each, so you can narrow your focus to those that best suit your circumstances. Call the programs or visit their websites to learn more.

To view programs that are best suited for you, select your insurance status for AXERT® or view all assistance programs

You may be eligible for one or more of the following programs:

To view programs that are best suited for you, select your insurance status for AXERT® or view all assistance programs

You may be eligible for one or more of the following programs:

At the current time, patient affordability programs for the selected insurance option are not available for this product. Please check back, as programs change.

The following programs are not affiliated with Janssen.

Be sure to contact the programs directly to get details on eligibility and application requirements, and to see if they have funding available to help you.

State-Sponsored Programs

Some states sponsor prescription financial assistance programs, each with its own eligibility requirements.

Find out if your state has a program that can help you »

Medicare Savings Program

Many states have programs for people with limited income and resources that pay some or all of Medicare's premiums and may pay Medicare deductibles and coinsurance. Find out if your state has a program that can help you.

Medicare Part D Extra Help — Low-Income Subsidy

Medicare patients who have limited income and resources may qualify for "extra help" to pay for prescription drugs. The Low-Income Subsidy (LIS) program from Medicare provides financial assistance for patients who may otherwise be unable to afford the costs associated with their Medicare Part D plan.

Those who are eligible for LIS may:

  • Receive assistance paying their monthly premium
  • Have a reduced or no deductible
  • Have reduced or no prescription coinsurance and co-payments
  • Have no gap in coverage
June 28, 2016
Expand
Expand

IMPORTANT SAFETY INFORMATION

INDICATIONS

AXERT® tablets are indicated for the acute treatment of migraine with or without aura in adults. AXERT® tablets are indicated for the acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated). In adolescents age 12-17 years, efficacy of AXERT® on migraine associated symptoms (nausea, photophobia and phonophobia) was not established.

AXERT® is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of AXERT® have not been established for cluster headache which is present in an older, predominantly male population.

AXERT® is a prescription medication for the acute treatment of migraine with or without aura in adults, and for the acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated). If you have no response for the first migraine attack treated with AXERT®, then your doctor will need to see if you really have migraine before you take AXERT® to treat any future attacks. You should not take AXERT® if you have heart disease, uncontrolled high blood pressure or have ever had heart disease. If you have risk factors for heart disease (high blood pressure, high cholesterol, diabetes, obesity, smoking, family history of heart attack, menopause, or are a male over 40 years of age), or if you are pregnant, nursing, or thinking about becoming pregnant, talk with your doctor before taking AXERT®. You should also tell your doctor if you have had a stroke of any type or any transient ischemic attacks, or if you have circulation (blood flow) problems, as you should not use AXERT®. Contact your doctor immediately if you are experiencing symptoms of pain, tightness, pressure, or heaviness in your chest, throat, neck, or jaw, shortness of breath, weakness, or slurring of speech, if you experience abdominal pain or bloody diarrhea, or if your fingers or toes become cold or discolored. In very rare cases, serious heart problems have occurred in patients without known heart disease.

AXERT®, like other triptans, may be associated with a potentially life-threatening condition mainly when taken together with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), two classes of drugs for depression or other disorders. Common SSRIs are Celexa® (citalopram HBr), Lexapro® (escitalopram oxalate), Paxil® (paroxetine), Prozac®/Sarafem® (fluoxetine), Symbyax® (olanzapine/fluoxetine), Zoloft® (sertraline), and Luvox® (fluvoxamine). Common SNRIs are Cymbalta® (duloxetine) and Effexor® (venlafaxine). If you experience symptoms such as confusion, sweating, flushing, rapid heartbeat, diarrhea, muscle weakness, poor balance, or worsening headache, contact your doctor immediately.

Tell your doctor about all prescription and over-the-counter medications you are taking. Do not take AXERT® if you have taken an ergotamine-containing or ergot-type medication or another triptan in the last 24 hours. Do not take if you have had an allergic reaction to AXERT® or any of its ingredients. Tell your doctor if you have had an allergic reaction to a sulfonamide drug or if you are taking ketoconazole.

The most common AXERT® side effects in adults are nausea, sleepiness, tingling sensation, headache, and dry mouth.

The most common AXERT® side effects in adolescents are dizziness, sleepiness, headache, tingling sensation, nausea and vomiting.

Ask your doctor about side effects, possible drug interactions, and any other important questions you may have before taking AXERT®.

Celexa and Lexapro are registered trademarks of Forest Laboratories. Paxil is a registered trademark of GlaxoSmithKline. Symbyax, Prozac/Sarafem and Cymbalta are registered trademarks of Eli Lilly. Zoloft is a registered trademark of Pfizer. Luvox is a registered trademark of Solvay. Effexor is a registered trademark of Wyeth.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

Please see full Product Information for more details.

IMPORTANT SAFETY INFORMATION

INDICATIONS

AXERT® tablets are indicated for the acute treatment of migraine with or without aura in adults. AXERT® tablets are indicated for the acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated). In adolescents age 12-17 years, efficacy of AXERT® on migraine associated symptoms (nausea, photophobia and phonophobia) was not established.

AXERT® is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of AXERT® have not been established for cluster headache which is present in an older, predominantly male population.

AXERT® is a prescription medication for the acute treatment of migraine with or without aura in adults, and for the acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated). If you have no response for the first migraine attack treated with AXERT®, then your doctor will need to see if you really have migraine before you take AXERT® to treat any future attacks. You should not take AXERT® if you have heart disease, uncontrolled high blood pressure or have ever had heart disease. If you have risk factors for heart disease (high blood pressure, high cholesterol, diabetes, obesity, smoking, family history of heart attack, menopause, or are a male over 40 years of age), or if you are pregnant, nursing, or thinking about becoming pregnant, talk with your doctor before taking AXERT®. You should also tell your doctor if you have had a stroke of any type or any transient ischemic attacks, or if you have circulation (blood flow) problems, as you should not use AXERT®. Contact your doctor immediately if you are experiencing symptoms of pain, tightness, pressure, or heaviness in your chest, throat, neck, or jaw, shortness of breath, weakness, or slurring of speech, if you experience abdominal pain or bloody diarrhea, or if your fingers or toes become cold or discolored. In very rare cases, serious heart problems have occurred in patients without known heart disease.

AXERT®, like other triptans, may be associated with a potentially life-threatening condition mainly when taken together with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), two classes of drugs for depression or other disorders. Common SSRIs are Celexa® (citalopram HBr), Lexapro® (escitalopram oxalate), Paxil® (paroxetine), Prozac®/Sarafem® (fluoxetine), Symbyax® (olanzapine/fluoxetine), Zoloft® (sertraline), and Luvox® (fluvoxamine). Common SNRIs are Cymbalta® (duloxetine) and Effexor® (venlafaxine). If you experience symptoms such as confusion, sweating, flushing, rapid heartbeat, diarrhea, muscle weakness, poor balance, or worsening headache, contact your doctor immediately.

Tell your doctor about all prescription and over-the-counter medications you are taking. Do not take AXERT® if you have taken an ergotamine-containing or ergot-type medication or another triptan in the last 24 hours. Do not take if you have had an allergic reaction to AXERT® or any of its ingredients. Tell your doctor if you have had an allergic reaction to a sulfonamide drug or if you are taking ketoconazole.

The most common AXERT® side effects in adults are nausea, sleepiness, tingling sensation, headache, and dry mouth.

The most common AXERT® side effects in adolescents are dizziness, sleepiness, headache, tingling sensation, nausea and vomiting.

Ask your doctor about side effects, possible drug interactions, and any other important questions you may have before taking AXERT®.

Celexa and Lexapro are registered trademarks of Forest Laboratories. Paxil is a registered trademark of GlaxoSmithKline. Symbyax, Prozac/Sarafem and Cymbalta are registered trademarks of Eli Lilly. Zoloft is a registered trademark of Pfizer. Luvox is a registered trademark of Solvay. Effexor is a registered trademark of Wyeth.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

Please see full Product Information for more details.